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propose the term “complex phase” Parkinson’s disease as 
an alternative which takes into account a multimodal symp-
toms and biomarker based approach in addition to patient 
preference.
Keywords Parkinson’s disease · Advanced · Complex · 
Nonmotor symptoms · Personalised medicine · Nonmotor 
subtypes
Introduction
The concept of “advanced Parkinson’s disease” (APD) 
remains controversial and unclear in spite of the extensive 
knowledge of the natural history of the motor syndrome of 
PD. Largely this relates to the complex pathophysiologi-
cal process involving dopaminergic and nondopaminergic 
pathways that underlies Parkinson’s disease (PD) (Uitti 
et al. 1993; Langston 2006). The concept of advanced PD 
has been examined in several studies with varying meth-
odologies ranging from retrospective audits to expert opin-
ion and Delphi system based studies usually using disease 
duration as one of the anchors (Table 1). The terminology 
has been confusing with varying nomenclature such as late 
stage or complex stage being used interchangeably while 
the concept of the palliative stage of PD has also evolved 
in recent times. The situation is further compounded by 
emergence of recent knowledge about the key importance 
of nonmotor symptoms (NMS) of PD, NMS being key 
determinants of quality of life and not necessarily progress-
ing hand in hand with motor progression of PD (Korczyn 
1999; Martinez-Martin et al. 2011; Coelho and Ferreira 
2012; Ray Chaudhuri et al. 2013). While advanced motor 
disease of PD is often associated with a disease duration of 
10–15 years and a range of non dopaminergic NMS such as 
Abstract Holistic management of Parkinson’s disease, 
now recognised as a combined motor and nonmotor disor-
der, remains a key unmet need. Such management needs 
relatively accurate definition of the various stages of Par-
kinson’s from early untreated to late palliative as each stage 
calls for personalised therapies. Management also needs 
to have a robust knowledge of the progression pattern and 
clinical heterogeneity of the presentation of Parkinson’s 
which may manifest in a motor dominant or nonmotor 
dominant manner. The “advanced” stages of Parkinson’s 
disease qualify for advanced treatments such as with con-
tinuous infusion or stereotactic surgery yet the concept of 
“advanced Parkinson’s disease” (APD) remains controver-
sial in spite of growing knowledge of the natural history 
of the motor syndrome of PD. Advanced PD is currently 
largely defined on the basis of consensus opinion and thus 
with several caveats. Nonmotor aspects of PD may also 
reflect advancing course of the disorder, so far not reflected 
in usual scale based assessments which are largely focussed 
on motor symptoms. In this paper, we discuss the prob-
lems with current definitions of “advanced” PD and also 
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Table 1  A summary of studies that have attempted to define advanced PD or late stage PD and provide treatment guidelines
Reference Type of study Population base Outcome
Hely et al. 
(2005)
Follow up of a cohort recruited to 
Bromocriptine vs low dose levodopa 
study
130 patients with 52 surviving at 
15 years
At 15 or more years falls, autonomic distur-
bance, neuropsychiatric symptoms, and 
dementia cause disability
Motor fluctuations and dyskinesias while com-
mon are less disabling
Hely et al. 
(2008)
Follow up of a cohort recruited to 
Bromocriptine vs low dose levodopa 
study
With 50 age and gender matched 
controls
30 surviving patients at 20 years FU 83% had dementia along with excessive 
daytime sleepiness 70%, falls 87%, freezing 
81%, symptomatic postural hypotension 
48%, urinary incontinence in 71%, hallucina-
tions in 74%
Coelho et al. 
(2010)
Cross-sectional analysis of an interna-
tional (Spain-Portugal) out patient 
cohort
50 PD patients in HY stages 4–5 (late 
stage)
UPDRS, nonmotor fluctuation, cognition 
and quality of life assessments
Motor and nonmotor (mainly non-levodopa 
responsive symptoms) were prevalent and 
the main cause of disability. 50%, however, 
were considered to be non-demented
Antonini 
et al. 
(2015)
Delphi panel—based on consensus a group of approximately 20 EU neurolo-
gists, using 2 rounds of data collec-
tion via an online survey and a single 
in-person meeting
Dementia, hallucinations, psychosis, non-
motor fluctuations, and nighttime sleep 
disturbances flagged as important potential 
hallmarks of advanced PD with functional 
consequences of falls, dependency and risk 
of pneumonia
Cilia et al. 
(2015)
Retrospective, cross-sectional study 
and longitudinal study
Patients with disease duration ≥ 20 years Older age at onset and longer disease dura-
tion independently associated with a higher 
prevalence of major motor and nonmotor 
milestones of disease
Mortality associated with male gender, older 
age, dysphagia, orthostatic hypotension, 
postural instability, fractures and institution-
alisation
Odin et al. 
(2015)
International expert recommendations 
for the management of PD refrac-
tory to oral/transdermal therapies
Collection and consensus of opinions on 
structured questions from 103 experts 
from 13 countries overseen by an 
International Steering Committee (ISC) 
with 13 movement disorder specialists
Patients requiring levodopa > 5 times daily 
with severe, troublesome ‘off’ periods 
(> 1–2 h/day) despite optimal oral/trans-
dermal levodopa or non-levodopa-based 
therapies considered for advanced therapies 
even if disease duration is < 4 years
Cognitive decline related to nonmotor fluc-
tuations is an indication for device-aided 
therapies
Luquin et al. 
(2017)
CEPA Study—a 3-round Delphi study Including neurologists in Spain and 
using a Delphi system identification 
and quantification of clinical variables 
that characterize patients with APD
Motor syndrome and sleep problems rated as 
key issues severe dysphagia, recurrent falls, 
and dementia
Hassan et al. 
(2015)
International, multicentre National 
Parkinson’s Foundation Quality 
Improvement Initiative (NPF-QII) 
study database used to identify 
PD-20 subjects
187 PD-20 subjects (55% men) (4% of 
all NPF-QII participants)
(75%) had 20-25 years of PD duration, longest 
duration being 49 years. PD-20 subjects 
reflect an elite group of PD survivors with 
early onset disease and relatively mild cogni-
tive disability despite long disease duration
dementia, advanced nonmotor burden of PD may also occur 
in early motor and even premotor disease (Sommer et al. 
2004; Zis et al. 2015; Sveinbjornsdottir 2016; Chahine 
et al. 2016). While none of the “neuroprotective” strategies 
attempted in clinical trials have been successful in PD pre-
sumably because of the inefficacy of the compounds tested, 
another cause may be because the therapy is only started 
at the motor stage of PD, not taking into account the pro-
dromal period when molecular neurodegeneration begins 
(Korczyn and Hassin-Baer 2015). Studies in experimen-
tal models of animals also show a variable association of 
disease severity with NMS (Titova et al. 2017a). This fact 
complicates the option of defining “advanced PD”. Fur-
thermore, recent concepts of nonmotor subtypes of PD also 
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indicates that there may be differential rates of progres-
sion of PD depending on the natural history of subtypes 
and hence assigning the concept of APD would need to be 
individualised as « one size » or definition of APD does 
not fit all (Korczyn 1999; Sauerbier et al. 2015; Marras and 
Chaudhuri 2016). The World Health Organisation interna-
tional classification of disorders (ICD) coding system cur-
rently has no definition for APD although many therapies 
such as levodopa or apomorphine infusion or deep brain 
stimulation (DBS) are indicated for APD (World Health 
Organization 2017). In addition, recently, a subgroup of 
PD has been described, the PD-20 subjects who inspite of 
20 years disease duration are relatively independent, show 
only mild cognitive impairment and some are still working 
(Hassan et al. 2015). Furthermore, patients often dislike 
the notion of being labelled with an APD diagnosis and a 
robust definition of APD would, therefore, be useful from 
a clinical, prescribing, licensing as well as epidemiological 
perspective (Table 2). The issue is also relevant for mean-
ingful information sharing. The problems of poor informa-
tion related to advancing PD and access to information on 
various “advanced” therapies have been highlighted in a 
Swedish patient survey of 486 patients where one of the 
criteria for APD was based on a diagnosis greater than 
5 years (Lokk 2011). 1300 subjects responded and 73% 
were given no information on advanced therapies for PD.
From a pathological point of view the concept of APD 
also remains unclear. Normally the concept of APD is 
underpinned by a progressive loss of nigrostriatal dopa-
minergic terminals which eventually disables the buffer-
ing capacity to manage fluctuations in striatal dopamine 
levels (Obeso 2008; Poewe 2010). But it is clear that 
there is also considerable loss of other neurotransmitter 
based neurons, sometimes even greater than the dopamin-
ergic loss, leading to the complex syndromic nature of 
PD (Korczyn 1999; Langston 2006; Titova et al. 2017b). 
Specifically, the gastrointestinal tract involvement at a 
cellular and molecular level is now well recognised and 
gastrointestinal dysfunction common across all stages of 
PD may lead to erratic/delayed gastric emptying. This 
may lead to significant changes in plasma levodopa bio-
availability related to oral medications (Jellinger 2015; 
Cerosimo 2012; Poewe 2010; Obeso 2008). Animal model 
and clinical studies suggest that emergence of motor com-
plications like on–off fluctuations and dyskinesias may 
therefore be linked at least in part to gastrointestinal dys-
function in addition to central loss of the buffering capac-
ity of the dopamine terminals as the disease progresses 
(Kordower et  al. 2013; Klingelhoefer and Reichmann 
2015; Titova et al. 2017b). These patients with PD are 
likely to exhibit the recently described adrenergic subtype 
of PD (Jellinger 2015; Titova et al. 2017b). In this paper 
we discuss these issues and attempt to better conceptual-
ise the definition of APD and also speculate as to whether 
APD could be better termed as complex phase PD with 
further relevant subclassifications. We derived the term 
“complex phase” PD from the concept of “Parkinson 
complex” originally coined and published by Langston 
in (2006).
Barriers for the concept of APD
Several issues as discussed above complicate the current 
attempts to define APD and are shown in Fig. 1. These also 
include recent knowledge that some prodromal symptoms 
Table 2  Why we should better define advanced PD
For patients
 Provide better biomarker based diagnostic and prognostic evaluation
 Improve acceptability of stage (terminology)
For health care professionals:
 Improve and consolidate the criteria for diagnosis of APD among clinicians providing standardised criteria
 Develop specific pathways which engage movement disorder specialists/“parkinsonologists” so that appropriate guidance for management is 
initiated early including multidisciplinary services
 Provide guidance for appropriate and timely implementation of advanced therapeutic options
 Develop appropriate toolkits and scales
For health care providers
 Early evaluation of relevant datasets in appropriate group of patients when described as advanced therapies
 Facilitate early reimbursement of therapies with reasonable evidence base in appropriate patient groups
 Define APD in WHO ICD coding handbook
For developing a true holistic concept
 Improve patient care and carer quality of life (affected by the term “advanced” with implications on lifestyle, prognosis as well as social inter-
action)
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such as cognitive impairment or REM behaviour disorder 
can dictate the course and severity of manifest PD in addi-
tion to the fact there is no specific robust biomarker that can 
accurately reflect APD.
The need for a robust definition of APD is important 
for several reasons and these concepts are articulated in 
Table 2. The issue is first and foremost of great importance 
to people with PD as the current uncertainties can cause 
problems with prognostic issues. Critically, it is clear that 
the prognosis and outcome of the course of PD cannot be 
generalised and individualisation, an important concept of 
the personalised medicine strategy is crucial. In addition, 
the term advanced is poorly accepted by many patients 
who in spite of a disease duration of 10 years or more may 
be active, independent as well as cognitively reasonably 
intact. This suggests disease duration is not a good indica-
tor of severity of PD as will be discussed later. A robust 
and clinically relevant definition of APD is first and fore-
most important for patients (Table 2). Clinical experience 
suggests that many patients resent being called “advanced” 
particularly if they are functionally active, able to be still 
working and socialise although with some limitations. Such 
case examples have been recorded in clinical experience. 
“Advanced” terminology also has considerable impact on 
working contracts, employer’s attitudes as well as inter-per-
sonal relationships. An alternative term that better defines 
an objective and dynamic way that defines “APD” is there-
fore important for patients.
Other factors include implications for health care profes-
sionals and commissioners/health care providers who need 
a standardised criterion which can influence pathways of 
treatment and in particular advanced therapies. The issue 
is of great importance for health care providers as well as 
commissioners who provide reimbursement for treatment 
based on a diagnosis of “APD” in some cases. A consist-
ent definition would reduce considerable variability in 
treatment as well as ensuring that patients are not denied 
advanced therapies when in spite of relevant symptoms they 
may not satisfy current definitions of APD. The rationale 
for development of evidence based medicine is based on 
this concept.
Problems of defining advanced PD with disease 
duration
Traditionally “long” disease duration has been the standard 
method and anchor by which APD has been defined although 
in most cases PD duration is really a secondary marker. Pub-
lications attempting to define APD thus comprises of alter-
native concepts of definition of APD, for instance, using a 
consensus versus those where a patients symptom-state at 
15, 20, or more years of duration were considered (Table 1). 
The latter concept therefore, was focussed on the predomi-
nant clinical manifestations at that time and described by 
staff of tertiary specialized centres and not gleaned from true 
population based data.
The length of the disease duration for PD to be consid-
ered as APD has been based on the duration of the “honey-
moon” period or “stable” PD and emergence of motor com-
plications (Sveinbjornsdottir 2016; Titova et al. 2017c). 
This length of disease duration is variable and in some 
studies a disease duration of 5 years has considered to be a 
short disease duration while in some studies a disease dura-
tion of 5–6 years is considered advanced disease (Simuni 
et al. 2013; Pistacchi et al. 2017; Politis et al. 2010; Lokk 
2011). Signs that have been thought to define APD have 
also been variable and a recent three round Delphi con-
sensus-based criteria has been proposed from the Spanish 
CEPA study (Luquin et al. 2017). In this consensus, the 
disease duration anchor of 10 years (median) was one of 
the markers for APD and in addition, definitive symptoms 
of APD included disability requiring help for the activi-
ties of daily living and/or severe dysphagia, recurrent falls, 
and dementia. However, several studies have examined PD 
patient cohorts with a disease duration of 20 years or more 
and most recently a study reported that this PD-20 cohort 
do not satisfy the criteria for APD as defined by the con-
sensus criteria (Hassan et al. 2015; Cilia et al. 2015). Dis-
ease duration alone therefore cannot truly map whether PD 
is advanced or not and certainly there is no “inevitability” 
about dementia at 20 years PD as has been suggested from 
the follow up report of the Sydney multicentre study (Hely 
Fig. 1  The conceptual and practical problems/barriers to the current 
attempts at defining advanced PD
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et al. 2008). In addition, subtle cognitive impairment has 
now been described in the prodromal stage of PD even 
before the motor symptoms are evident (Weintraub et al. 
2015; Chahine et al. 2016). The uncertainty about defini-
tion of APD is also reflected in the current International 
Classification of Disorders Classification of Parkinson’s 
Disease where currently, there is no subcode specifically 
for APD [World Health Organization (2017) G20: Parkin-
son disease].
As discussed before, several workers have addressed 
the concept of APD, some using a longer disease duration 
(10–20 years) as anchor, but as a secondary marker (Hely 
et al. 2005, 2008; Cilia et al. 2015). Symptoms included are 
a range of motor and nonmotor symptoms while others have 
relied on expert opinion based or Delhi type consensus.
In a meta-analysis performed by Chen et al. (2015) the 
duration of illness primarily correlated with the frequency 
of constipation and excessive daytime sleepiness. However, 
symptoms such as apathy, attention/memory, psychiatric 
symptoms did not correlate with disease duration. In par-
ticular, psychiatric NMS, mainly anxiety and depression, 
were reported by 61.1% of patients at Hoehn and Yahr stage 
1 illustrating the problems of defining disease severity of PD 
with disease duration (Chen et al. 2015). This observation as 
well as the variability of the outcome in studies as shown in 
Table 1 underpins the need to develop a multimodal strategy 
for defining APD and not just rely on disease duration, and 
symptom occurrence.
Are there biomarkers for advanced PD?
Biomarkers are important to support the concept of APD 
and can be classified to (Sharma et al. 2013; Titova et al. 
2017c).
• In vivo (neuroimaging, neurophysiology, polysomnogra-
phy)
• In vitro (biochemical/genetics from tissue samples)
• Pathological (α-synuclein)
• Neuroimaging: dopamine transporter loss (Datscan puta-
men binding ratios), iron accumulation (cranial ultra-
sound)
• Neurobehavioral (depression, fatigue, cognition)
• Other clinical symptoms
Lerche et al. (2016) has proposed a set of clinical and 
objective biomarkers to better define stages in longitudi-
nal studies of PD. Nine modalities ranging from motor, 
neuropsychiatric, other nonmotor clinical symptoms to 
imaging and blood based and other biomarkers such as 
skin biopsy have been proposed. Specifically, autonomic, 
gastrointestinal, sleep and sensory nonmotor measurements 
are listed. A recent study has highlighted the possible role 
of skin biopsy and detection of abnormal alpha synuclein 
in cases with rapid eye movement behaviour disorder 
(Doppler et al. 2017). These modalities may be useful for 
research based studies, but for real life clinical assess-
ment of APD a more pragmatic and simpler paradigm is 
required. Kruger et al. (2017) have proposed the concept of 
“deep phenotyping” which includes device based assess-
ments (such as accelerometers or smartphones), molecular 
and genetic biomarkers as well as clinical subtyping of 
patients to better define the stages of PD leading to per-
sonalised precision medicine delivery. However, the role 
of biomarkers to define APD is far from clear. A battery of 
biomarkers is clearly required and recent evidence from a 
2-year follow up study of de novo PD suggests that single 
and cognitive biomarkers are not be adequate to map pro-
gression of PD (Mollenhauer et al. 2016). Thirty possible 
biomarkers were examined in this study and the authors 
conclude that a multimodal approach, with clinical, bio-
chemical, and laboratory based biomarkers, is needed 
(Mollenhauer et al. 2016). It must be recognised, however, 
that at present modalities such as transcranial ultrasound 
or skin biopsy remains investigational as biomarkers. 
Dopamine transporter imaging while useful as a surrogate 
marker for dopaminergic deficiency remains impractical 
for routine use because of cost.
A important new advance is the role of technology-
based devices which can be classified to wearable, non 
wearable, and hybrid devices (Godinho et al. 2016; Bhi-
dayasiri and Martinez-Martin 2017). Early findings from 
studies assessing the role of applications of these tech-
nologies suggest that these technologies may support and 
effectively track the clinical assessment of motor features 
of PD, certain NMS such as sleep, as well as gait, mobility, 
risk of falls daily living transitions, and physical activi-
ties. Several of these symptoms are included in the Delphi 
consensus based definition of APD (Antonini et al. 2015) 
and as such these devices may serve as possible biomark-
ers and, importantly, provide objective data supporting the 
diagnosis of the APD state.
How can the concept of APD be improved? 
Proposal to change terminology to complex PD
It is clear that our current concept APD is plagued by sev-
eral problems including unclear transitional milestones 
when stable PD becomes unstable PD or early PD becomes 
APD. The syndromic nature of PD, multi neurotransmitter 
involvement, motor and nonmotor subtypes of PD, variable 
and unclear progression pattern of motor and nonmotor 
symptoms and recent mapping of several NMS marking 
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prodromal PD make a clear definition of APD inaccurate 
as largely the concept is underpinned by disease duration. 
Feedback from patient groups as well as clinical experi-
ence suggests that some patients also are troubled by the 
term APD when they may still be relatively independent. 
Our proposal is that a better alternative terminology to use 
would be complex phase PD. Complex phase PD would 
encompass the basic concept of the complex origins of 
PD as well as the heterogeneity of its clinical presenta-
tion. Factors and mechanisms that may support the concept 
of using the term complex phase PD instead of APD are 
shown in Table 3.
Currently there is no consensus or list of factors that 
may constitute the definition of complex phase PD. Our 
proposal is that several factors as shown in Table 4 which 
takes into account the list of enablers shown in Table 3 
could be used to define complex phase PD. Clinically this 
will include gradation of PD using a cumulative grading 
system of motor and nonmotor symptoms. Such scales and 
its burden grading has been described and the most prag-
matic and easy to use system would be the combination 
of the Hoehn and Yahr staging (HY, motor) with nonmo-
tor burden grading either using the NMS questionnaire 
or NMS scale (Sauerbier et al. 2015). NMSQuest grad-
ing is currently the only validated NMS grading using 
a patient related outcome measure. Alternative grading 
systems could also be used such as combining HY stag-
ing with the part 1 of the movement disorder society uni-
fied Parkinson’s disease rating scale (MDS-UPDRS). This 
strategy moves away from specific motor and NMS which 
have been cited in the consensus criteria for APD as such 
symptoms can also occur in “early” PD. Examples would 
be, the occurrence of cognitive impairments in prodromal 
PD as well as a considerable burden of NMS even in drug 
naïve PD (Chahine et al. 2016; Zis et al. 2015). However, 
such a strategy alone would not be sufficient. In addition, 
the complexity of PD and need for advanced therapies 
would also be underpinned by failure of “conventional 
therapies, usually oral and transdermal dopamine replace-
ment therapies as well as emergence of troublesome motor 
and nonmotor fluctuations to levodopa therapy. The clini-
cal grading would need to be supported by selected bio-
markers. As discussed above currently, the role of these 
biomarkers are unclear but based on clinical experience 
low putamen binding ratios on Datscan and or low caudate 
and putamen binding rations can be used to mark com-
plex PD. In future sophisticated MRI imaging techniques 
such as T2-weighted fluid-attenuated inversion recovery 
sequences for detection of nigral or basal forebrain degen-
eration, diffusion tensor imaging for subcortical white 
matter degeneration as well as voxel-based morphometry 
may also emerge as useful surrogate biomarkers. The role 
of device based assessments (accelerometry based tracking 
of bradykinesia as well as dyskinesia and some nonmo-
tor symptoms) is being investigated and such tools are 
already in routine clinical use in many countries. Finally, 
the role of personalised medicine for PD has merged as 
a specific and not simply a genomic strategy (Titova and 
Chaudhuri 2017). Complexity of PD should therefore, 
also take into consideration the factors that complete the 
“circle” of personalised medicine and specifically assess-
ment of personality traits. A summary of proposed factors 
that could constitute the concept of complex phase PD is 
shown in Table 4.
It is also conceivable that in future one would be able to 
define patients who may be “at risk” of developing complex 
Table 3  Enablers and factors that may suggest the term complex phase PD is a better term to use to denote advanced Parkinson’s disease (PD)
Patient preference
Complexity of mechanisms that lead to the clinical expression of motor and nonmotor subtypes of PD
The need for multimodal and not single biomarkers
The need to take into account various strands of personalised medicine
The fact that advanced PD implies duration of disease while complex refers to the conditional stage and incorporates the concept that early PD 
can also be complex
Table 4  Factors proposed to define complex phase PD
HY Hoehn and Yahr, NMSSB nonmotor symptoms scale derived burden, NMSQB nonmotor symptoms questionnaire based burden
Combination of motor and NMS grading using a combined grading system (HY + NMSSB or HY + NMSQB)
Falling or failing response to oral/transdermal DRT therapy with emergence of motor and nonmotor fluctuations
Datscan showing low (dependent on local laboratory estimates) putamen or combined putamen and caudate binding ratios
Accelerometry based dataset indication and supporting clinical impression of severe bradykinesia or troublesome dyskinesia at home. (Addition-
ally some nonmotor data may also become available such as an indication of sleep function)
Presence of personality trait based factors necessitating the delivery personalised medicine
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PD perhaps earlier than other patients with PD. Such 
patients may be the ones with severe and troublesome RBD 
during the prodromal stage who are more likely to have cog-
nitive dysfunction, dysautonomia as well as falls (Postuma 
et al. 2015). Olfactory dysfunction may further enhance the 
development of dementia (Takeda et al. 2014). In addition, 
we would envisage that complex phase PD could also be 
stratified to subgroups based on clinical neurotransmitter 
dysfunction driven subtypes, complex early and complex 
advanced stages, biomarkers, response to current therapies 
as measured by the APD toolkit.
Scales and toolkit for complex phase PD
Attempts to develop a validated toolkit for better definition 
of APD have been initiated. The toolkit is based on measure-
ment of inadequate control with oral anti-PD medications 
as well as a frequency ad severity graded assessment of a 
collection of motor, nonmotor symptoms (nonmotor fluctua-
tions, psychosis and impulse control disorders) and symp-
toms of functional impact (frequency of falls and increased 
dependency) (Antonini et al. 2017). Validation of this toolkit 
is awaited. Whether such a toolkit will accurately reflect our 
concept of complex phase PD also remains to be tested.
Conclusion
The term APD remains poorly defined and a robust defini-
tion remains an unmet need inspite of consensus opinion. 
Patient acceptance of the definition of advanced PD is poor 
and clinically the concept needs to include our growing 
knowledge of the heterogeneity and syndromic nature of PD 
underpinned by motor and nonmotor subtypes as well as 
the variable progression pattern of the motor and nonmotor 
aspects of the disorder. The issue is of great importance as 
provision for advanced therapies for PD and personalised 
medicine strategies are based on the current definition of 
APD. We propose an alternative approach to the concept of 
defining APD which may be better termed complex phase 
PD taking into account a clinical and biomarker based mul-
timodal approach. This concept needs to be examined in real 
life studies and may better define the prospect of personal-
ised medicine delivery as well as prognostic aspects of this 
complex disorder.
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